Wrap Text
Audited Annual Financial Statements for the year ended 31 March 2025
Cilo Cybin Holdings Limited
Incorporated in the Republic of South Africa
(Registration number 2022/320351/06)
Share code: CCC ISIN: ZAE000310397
("Cilo Cybin" or "the Company")
AUDITED ANNUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
Introduction
Cilo Cybin is pleased to announce its results for the year ended 31 March 2025, which reflect the Company's continued
commitment to executing its strategic objectives and delivering value to its shareholders.
Review of activities
The Company's main operations are identifying viable investments in Biotech, Biohacking and Pharmaceutical businesses.
Operational Update
The Company entered into a share purchase agreement ("Agreement") with the shareholders of Cilo Cybin Pharmaceutical
Proprietary Limited ("CC Pharmaceutical") in November 2024. In terms of the Agreement, and subject to the fulfilment of the
conditions precedent, the Company will acquire all the issued shares in CC Pharmaceutical from the Sellers for an aggregate
purchase consideration of R845 million to be settled through the issue of the Company's ordinary shares.
Basis of preparation
The financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International
Accounting Standards Board (IASB), the JSE Listings Requirements and the requirements of the Companies Act, 71 of 2008, as
amended. The accounting policies have been applied consistently compared to the prior year. The operating results and statement
of financial position of the Company are fully set out in the attached financial statements and do not in our opinion require any
further comment.
Key features for the year
Figures in Rands (unless otherwise stated) FY 2025 FY 2024 % Change
Revenue - -
Cost of sales - -
Gross profit - - -
Other income - -
Investment revenue 4,828,827 1,064,093 354%
Administrative expenditure (5,097,635) (564,264) 803%
Operating profit / (loss) (268,808) 499,829 -154%
Finance costs (316,908) (44,394) 614%
Profit / (Loss) before taxation (585,716) 455,435 -229%
Taxation - -
Profit / (Loss) for the period (585,716) 455,435 -229%
Other comprehensive income - -
Total comprehensive profit / (loss) (585,716) 455,435 -229%
Basic (loss) / earnings per share (cents) (0.85) 0.51 -267%
Dilutive (loss) / earnings per share (cents) (0.85) 0.51 -267%
- Investment income increased by 354% to R4.829 million (Mar 2024: R1.064 million) and is as a result of the money raised in
the Initial Public Offer ("IPO") that is currently held in an Escrow account until the Company completes the acquisition of
Viable Assets.
- Loss for the period of R585.7 thousand was recorded (Mar 2024: R455.4 thousand)
- Cash outflows from operations amounted to R2.083 million (Mar 2024: R632.3 thousand cash inflow)
- Basic earnings per share declined to 0.85 cents per share (Mar 2024: 0.51 cent per share)
- 7 101 791 ordinary shares were issued following completion of the subscription process associated with an IPO
- The Company listed on the AltX on 25 June 2024
The business had a cash outflow from operating activities of R2.083 million, ending the period with cash and cash equivalents of
R58.3 million. The increase in expenditure was in line with a deliberate focus to appoint service providers to commence with the
process of acquiring a Viable Asset.
Accounting Policies
The accounting policies applied in the preparation of the Results are in terms of the IFRS and are consistent with those applied in
the annual financial statements for the year ended 31 March 2024, including the new and amended IFRS that became effective
during the 31 March 2025 reporting period, none of which had a material impact on the Company's financial results.
The Results have been prepared under the historical cost convention.
The Results were prepared under the supervision of Ms R.M Ledwaba (CA) SA in her capacity as Chief Financial Officer.
Results Announcement
This results announcement is the responsibility of the board of directors of the Company ("Board"). This results announcement
does not include full or complete details of the audited annual financial statements for the year ended 31 March 2025 ("2025 AFS")
released on SENS on 27 June 2025. Any investment decision made by investors and/or shareholders should be based on a
consideration of the 2025 AFS as a whole. None of the information contained in this announcement has been reviewed or reported
on by the Company's auditors.
The 2025 AFS have been audited but the Company's auditor, Nexia SAB&T, who expressed an unmodified opinion thereon. The
full 2025 AFS can be found on the Company's website at www.cilocybin.com and on the JSE's cloudlink at:
https://senspdf.jse.co.za/documents/2025/jse/isse/ccce/AFS2025.pdf
By order of the Board
GC Theron (Chief Executive Officer)
RM Ledwaba (Chief Financial Officer)
Corporate information
Executive directors: Gabriel Christiaan Theron, Reshoketswe Maggy Ledwaba
Non-executive directors: Sakekile Baduza (Independent) ,Dr Tham Seng Kong (Chairman), Daktuk Mohd Razef Adbullah
(Independent), Cindee Chew Yoke Ling (Independent), Wei Sim (Amanda) Low (Independent), Lisa Teoh (Independent), Jessica
Moodley-Theron
Designated Adviser: Merchantec Capital
Company Secretary: Acorim Proprietary Limited
Commercial bankers: First National Bank
Registered office: The registered office, which is also the principal place of business, is:
23 Sterling Road, Unit E4 The Point Office Park, Samrand, 0157
Transfer secretaries: Computershare Investor Services Propietary Limited
www.cilocybin.co.za
Centurion
30 June 2025
Date: 30-06-2025 10:37:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
